EichorEICHOR
Study identifier: NCT07573215 Synced from ClinicalTrials.gov · August 02, 2026
● Available

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Condition: PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Metastatic Pancreas Adenocarcinoma  ·  Sponsor: Revolution Medicines, Inc.

PhaseN/A
Planned participants
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.

This description comes directly from the study's public registry record.

Talk to the study team

Revolution Medicines Study Director  ·  1-844-2-REVMED  ·  medinfo@revmed.com

Always discuss trial participation with your own doctor first.

Locations (170)

Southern Cancer CenterDaphne, Alabama, United StatesAvailable
Southern Cancer CenterMobile, Alabama, United StatesAvailable
Alaska Oncology and HematologyAnchorage, Alaska, United StatesAvailable
Cancer and Blood Specialists of ArizonaCasa Grande, Arizona, United StatesAvailable
Mayo Clinic - ArizonaPhoenix, Arizona, United StatesAvailable
Honor HealthScottsdale, Arizona, United StatesAvailable
University of Arizona Cancer CenterTucson, Arizona, United StatesAvailable
Mercy Hospital Fort SmithFort Smith, Arkansas, United StatesAvailable
Genesis Cancer and Blood InstituteHot Springs, Arkansas, United StatesAvailable
Care Oncology CenterChula Vista, California, United StatesAvailable
City of Hope Cancer Center (California)Duarte, California, United StatesAvailable
Cancer and Blood Specialty ClinicsFountain Valley, California, United StatesAvailable

+ 158 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →